News | January 06, 2012

Fully Automated CT Lung Cancer Detection System Makes Progress

CT Lung cancer detection

January 6, 2012 – A firm developing a noninvasive test for the early detection of lung cancer and other applications today reported that it had achieved full automation of its Cell-CT system - a proprietary imaging platform that generates high-resolution 3-D biosignatures from intact cells. Development of the fully automated system, by the company, VisionGate, Inc., was funded in part by a $2.6 million grant from the National Institutes of Health's (NIH) Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies program (BRDG-SPAN).

VisionGate's first diagnostic application for the automated Cell-CT system is the LuCED test, a non-invasive test in development for lung cancer screening. LuCED and the Cell-CT platform produce detailed 3-D images of cells in sputum, which the system automatically analyzes to identify key features, or biosignatures, associated with potential malignancy. The analysis yields a score that indicates whether or not cancer cells are present. The Cell-CT system produces clear and comprehensive 3-D images of the cells, enabling extremely accurate classifications. LuCED is initially being developed for use in conjunction with x-ray CT screening, which has been shown to reduce lung cancer deaths in high-risk individuals, but which also has a high rate of false positive results. LuCED is expected to greatly reduce the incidence of false positives, potentially enabling the approach to be used for cost-effective lung cancer screening on a mass scale.

“We believe the automated Cell-CT platform could revolutionize cell-based diagnostics, both by enabling early disease detection and by providing pathologists with a powerful new tool for a wide range of applications,” said Alan Nelson, Ph.D, chairman and CEO of VisionGate. "In the near-term, automation of the Cell-CT platform sets the stage for submission of our first applications to the Food and Drug Administration (FDA) later this year for regulatory review of LuCED."

In a July 2011 presentation at the International Academy for the Study of Lung Cancer's 14th World Conference on Lung Cancer, VisionGate showed how LuCED and the Cell-CT platform could accurately detect cancer cells in sputum samples from individuals at high risk of lung cancer.

"The Cell-CT 3-D imaging system could be a valuable tool for early detection of lung cancer, when the disease is potentially curable," said David Yankelevitz, M.D., professor of radiology and director of the lung biopsy service at the Mount Sinai Medical Center in New York City. "But the large number of individuals at high risk for developing this disease, which kills more than 160,000 Americans annually, mandates that screening be accurate, efficient and cost effective. Automation of this innovative diagnostic tool is an important step towards achieving these performance requirements."

The Cell-CT automated system uses optics and computational technology that have the capability to capture images rapidly and render scanned objects into 3-D digital images. All components of the Cell-CT system have been custom-designed by VisionGate's and the technology is covered by 66 issued patents around the globe.

The BRDG-SPAN program aims to accelerate the transition of research innovations and technologies toward the development of products or services that will improve human health, help advance the mission of NIH and its affiliates, and create significant value and economic stimulus. This program also aims to foster partnerships among a variety of R&D collaborators working toward these aims.

VisionGate will be presenting at the 2012 OneMedForum Finance Conference in San Francisco on Tuesday, January 10, 2012.

For more information: www.visiongate3D.com, http://www.nhlbi.nih.gov/recovery/funding/small-biz-prog.htm

Related Content

Videos | Artificial Intelligence | December 13, 2018
ITN Editor Dave Fornell and ITN Contributing Editor Greg Freiherr share their insights on the vendors showing AI prod
Canon Aquilion One CT Helps Gates Vascular Institute Adhere to New Stroke Guidelines
News | Computed Tomography (CT) | December 12, 2018
In stroke, time saved on imaging is time gained in the treatment window. The recently updated guidelines from the...
Coreline Soft Introduces AI Lung Segmentation Solution at RSNA 2018
News | Lung Cancer | December 10, 2018
December 10, 2018 — Korean image software company Coreline Soft Co. Ltd.
FDA Approves New Features for Planmed Verity Cone Beam CT Scanner
Technology | Computed Tomography (CT) | December 07, 2018
The U.S. Food and Drug Administration (FDA) issued an approval letter for the new features and intended uses of the...
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...
YITU Releases AI-Based Cancer Screening Solutions at RSNA 2018
News | Artificial Intelligence | December 06, 2018
Chinese artificial intelligence (AI) healthcare company YITU healthcare released two brand-new products, Intelligent...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
GE Healthcare Unveils New Applications and Smart Devices Built on Edison Platform
Technology | Artificial Intelligence | December 05, 2018
GE Healthcare recently announced new applications and smart devices built on Edison – a platform that helps accelerate...
Fujifilm Collaborates With Lunit on AI Pilot Project
News | Artificial Intelligence | December 05, 2018
Fujifilm Medical Systems USA Inc. announced a joint collaboration with Korean-based medical artificial intelligence (AI...
ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...